Department of Aged Care, The Northern Hospital, Epping, Victoria, Australia.
Am J Cardiol. 2012 May 1;109(9):1365-73. doi: 10.1016/j.amjcard.2011.12.032. Epub 2012 Feb 28.
The prognostic usefulness of the cardiac biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP) and angiotensin-converting enzyme 2 (ACE-2), in predicting adverse cardiac outcomes after orthopedic surgery is not well studied. The aim of our study was to determine the usefulness of perioperative NT-proBNP and ACE-2 for predicting cardiac events after emergency orthopedic surgery. The perioperative NT-proBNP and ACE-2 levels were determined in 187 consecutive patients aged >60 years who underwent orthopedic surgery with 1 year of follow-up for any cardiac complications (defined as acute myocardial infarction, congestive cardiac failure, atrial fibrillation, or major arrhythmia) and death. Of the 187 patients, 20 (10.7%) sustained an in-hospital postoperative cardiac complication. The total all-cause in-hospital and 1-year mortality rate was 1.6% (3 of 187) and 8.6% (16 of 187), respectively. The median preoperative and postoperative NT-proBNP level was greater in patients who sustained an in-hospital cardiac event than in those who had not (386 vs 2,273 pg/ml, p <0.001, and 605 vs 4,316 pg/ml, p <0.001, respectively). Similarly, the postoperative median ACE-2 levels were significantly greater in the patients with an in-hospital cardiac event than in those without (25.3 vs 39.5 pmol/ml/min, p = 0.012). A preoperative NT-proBNP level of ≥741 pg/ml (odds ratio 4.5, 95% confidence interval 1.3 to 15.2, p = 0.017), postoperative troponin elevation (odds ratio 4.9, 95% confidence interval 1.3 to 18.9, p = 0.022), and number of co-morbidities (odds ratio 1.8, 95% confidence interval 1.2 to 2.8, p = 0.009) independently predicted in-hospital cardiac complications on multivariate analysis. The pre- and postoperative NT-proBNP level independently predicted 1-year cardiovascular complications but not the ACE-2 levels. In conclusion, elevated perioperative NT-proBNP predicted in-hospital and 1-year cardiac events in an emergency orthopedic population but the ACE-2 levels did not, which requires additional study for validation.
心脏生物标志物 N 末端脑利钠肽前体(NT-proBNP)和血管紧张素转换酶 2(ACE-2)在预测骨科手术后不良心脏结局方面的预后价值尚未得到充分研究。我们的研究旨在确定围手术期 NT-proBNP 和 ACE-2 预测急诊骨科手术后心脏事件的有用性。对 187 例年龄>60 岁的连续患者进行了围手术期 NT-proBNP 和 ACE-2 水平测定,这些患者在 1 年的随访期间发生任何心脏并发症(定义为急性心肌梗死、充血性心力衰竭、心房颤动或主要心律失常)和死亡。在 187 例患者中,20 例(10.7%)发生院内术后心脏并发症。总院内和 1 年全因死亡率分别为 1.6%(3/187)和 8.6%(16/187)。与未发生院内心脏事件的患者相比,发生院内心脏事件的患者的术前和术后中位 NT-proBNP 水平更高(386 与 2273 pg/ml,p<0.001,605 与 4316 pg/ml,p<0.001)。同样,发生院内心脏事件的患者的术后中位 ACE-2 水平显著高于未发生的患者(25.3 与 39.5 pmol/ml/min,p=0.012)。术前 NT-proBNP 水平≥741 pg/ml(优势比 4.5,95%置信区间 1.3 至 15.2,p=0.017)、术后肌钙蛋白升高(优势比 4.9,95%置信区间 1.3 至 18.9,p=0.022)和合并症数量(优势比 1.8,95%置信区间 1.2 至 2.8,p=0.009)在多变量分析中独立预测院内心脏并发症。术前和术后 NT-proBNP 水平独立预测 1 年心血管并发症,但 ACE-2 水平未预测,这需要进一步的验证研究。